User login
Christopher Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS) will deliver the keynote luncheon address on the first day of the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, to take place in Arlington, Virginia, on Oct. 21–22. Dr. Austin will speak on drug repurposing and identifying possible connections between existing therapies and rare diseases. Other keynote speakers will include Stephen Ostroff, MD, Acting Commissioner of the Food and Drug Administration (FDA), and Jono Lancaster of the UK, who will describe his experiences as a patient living with a rare disease—Treacher Collins syndrome.
The NORD Summit draws approximately 500 participants each year, including medical professionals, senior staff of the NIH and FDA, leaders of patient organizations, and pharmaceutical industry thought leaders.
An up-to-the-minute agenda and online registration are available through the NORD website.
Christopher Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS) will deliver the keynote luncheon address on the first day of the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, to take place in Arlington, Virginia, on Oct. 21–22. Dr. Austin will speak on drug repurposing and identifying possible connections between existing therapies and rare diseases. Other keynote speakers will include Stephen Ostroff, MD, Acting Commissioner of the Food and Drug Administration (FDA), and Jono Lancaster of the UK, who will describe his experiences as a patient living with a rare disease—Treacher Collins syndrome.
The NORD Summit draws approximately 500 participants each year, including medical professionals, senior staff of the NIH and FDA, leaders of patient organizations, and pharmaceutical industry thought leaders.
An up-to-the-minute agenda and online registration are available through the NORD website.
Christopher Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS) will deliver the keynote luncheon address on the first day of the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, to take place in Arlington, Virginia, on Oct. 21–22. Dr. Austin will speak on drug repurposing and identifying possible connections between existing therapies and rare diseases. Other keynote speakers will include Stephen Ostroff, MD, Acting Commissioner of the Food and Drug Administration (FDA), and Jono Lancaster of the UK, who will describe his experiences as a patient living with a rare disease—Treacher Collins syndrome.
The NORD Summit draws approximately 500 participants each year, including medical professionals, senior staff of the NIH and FDA, leaders of patient organizations, and pharmaceutical industry thought leaders.
An up-to-the-minute agenda and online registration are available through the NORD website.
